ASX:VTI

Stock Analysis Report

Visioneering Technologies

Executive Summary

Visioneering Technologies, Inc., a medical device company, engages in the design, manufacture, sale, and distribution of contact lenses in the United States.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has Visioneering Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

5.3%

VTI

2.4%

AU Medical Equipment

-0.2%

AU Market


1 Year Return

-55.6%

VTI

31.8%

AU Medical Equipment

10.5%

AU Market

Return vs Industry: VTI underperformed the Australian Medical Equipment industry which returned 31.8% over the past year.

Return vs Market: VTI underperformed the Australian Market which returned 10.5% over the past year.


Shareholder returns

VTIIndustryMarket
7 Day5.3%2.4%-0.2%
30 Day17.6%3.1%-1.4%
90 Day19.4%3.4%-1.0%
1 Year-55.6%-55.6%34.1%31.8%16.9%10.5%
3 Yearn/a52.9%46.2%36.9%18.6%
5 Yearn/a143.7%124.0%50.2%16.2%

Price Volatility Vs. Market

How volatile is Visioneering Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Visioneering Technologies undervalued compared to its fair value and its price relative to the market?

4.88x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate VTI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate VTI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: VTI is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: VTI is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VTI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VTI is overvalued based on its PB Ratio (4.9x) compared to the AU Medical Equipment industry average (4.7x).


Next Steps

Future Growth

How is Visioneering Technologies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

39.2%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if VTI's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if VTI's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: VTI's revenue (39.2% per year) is forecast to grow faster than the Australian market (3.6% per year).

High Growth Revenue: VTI's revenue (39.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VTI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Visioneering Technologies performed over the past 5 years?

-25.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: VTI is unprofitable, and losses have increased over the past 5 years at a rate of -25.6% per year.

Accelerating Growth: Unable to compare VTI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VTI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (29.5%).


Return on Equity

High ROE: VTI has a negative Return on Equity (-442.24%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: VTI is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: VTI is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Visioneering Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: VTI's short term assets ($3.9M) exceeds its short term liabilities ($1.3M)

Long Term Liabilities: VTI's short term assets (3.9M) exceeds its long term liabilities (253.0K)


Debt to Equity History and Analysis

Debt Level: VTI is debt free.

Reducing Debt: VTI had no debt 5 years ago.


Balance Sheet

Inventory Level: VTI has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if VTI's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VTI has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: VTI has less than a year of cash runway if free cash flow continues to reduce at historical rates of -24.8% each year


Next Steps

Dividend

What is Visioneering Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.4%markettop25%5.6%industryaverage1.6%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate VTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate VTI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if VTI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VTI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VTI's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

What is the CEO of Visioneering Technologies's salary, the management and board of directors tenure and is there insider trading?

2.5yrs

Average management tenure


CEO

Stephen Snowdy (49yo)

6.3yrs

Tenure

0

Dr. Stephen Snowdy, Ph,D., has been Chief Executive Officer of Visioneering Technologies, Inc. June 2013 and serves as its President and Executive Director. Dr. Snowdy is a Principal at Memphis Biomed Vent ...


Management Age and Tenure

2.5yrs

Average Tenure

Experienced Management: VTI's management team is considered experienced (2.5 years average tenure).


Board Age and Tenure

2.4yrs

Average Tenure

54yo

Average Age

Experienced Board: VTI's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$792,61209 Jul 19
Regal Funds Management Pty Limited
EntityCompany
Shares15,132,697
Max PriceUS$0.059
BuyUS$527,68909 Jul 19
Regal Funds Management Pty Limited
EntityCompany
Shares9,772,245
Max PriceUS$0.054
BuyUS$203,94017 Jun 19
Thorney Technologies Ltd
EntityCompany
Shares4,480,784
Max PriceUS$0.11
BuyUS$809,19817 Jun 19
TIGA Trading Pty Ltd, Asset Management Arm
EntityCompany
Shares17,862,572
Max PriceUS$0.11
SellUS$151,08314 Jun 19
Regal Funds Management Pty Limited
EntityCompany
Shares2,427,833
Max PriceUS$0.064
BuyUS$1,929,92512 Jun 19
Paul Cozzi
EntityIndividual
Shares20,082,748
Max PriceUS$0.096
SellUS$218,38313 May 19
Regal Funds Management Pty Limited
EntityCompany
Shares2,364,325
Max PriceUS$0.092
BuyUS$2,07013 May 19
Regal Funds Management Pty Limited
EntityCompany
Shares30,000
Max PriceUS$0.069
SellUS$40,85116 Apr 19
Renaissance Smaller Companies Pty Ltd
EntityCompany
Shares524,548
Max PriceUS$0.078
SellUS$136,60311 Apr 19
Renaissance Smaller Companies Pty Ltd
EntityCompany
Shares1,394,495
Max PriceUS$0.098
BuyUS$299,99911 Apr 19
Renaissance Smaller Companies Pty Ltd
EntityCompany
Shares1,666,667
Max PriceUS$0.18
SellUS$53,67604 Apr 19
Kinetic Investment Partners Limited
EntityCompany
Shares808,755
Max PriceUS$0.066
BuyUS$61,47706 Mar 19
Kinetic Investment Partners Limited
EntityCompany
Shares354,743
Max PriceUS$0.17
SellUS$61,47706 Mar 19
Kinetic Investment Partners Limited
EntityCompany
Shares354,743
Max PriceUS$0.17
SellUS$496,64126 Feb 19
Regal Funds Management Pty Limited
EntityCompany
Shares3,313,767
Max PriceUS$0.15

Ownership Breakdown


Management Team

  • Brian Lane (57yo)

    Chief Financial Officer

    • Tenure: 0.8yrs
  • Stephen Snowdy (49yo)

    CEO, President & Executive Director

    • Tenure: 6.3yrs
  • Tony Sommer

    Senior Vice President of Sales & Marketing

    • Tenure: 3.1yrs
  • Julian Rockett

    Company Secretary

    • Tenure: 0.7yrs
  • Richard Griffin

    Founder & Medical Adviser

    • Tenure: 0yrs
  • Rosa Lee

    Executive Director of Manufacturing & Engineering

    • Tenure: 2.8yrs
  • Layna Mendlinger

    Executive Director of Marketing

    • Tenure: 0yrs
  • Sally Dillehay

    Chief Medical Officer

    • Tenure: 0yrs
  • Doug Benoit

    Executive Director of Professional Affairs

    • Tenure: 2.1yrs

Board Members

  • Christi van Heek (62yo)

    Non-Executive Director

    • Tenure: 0yrs
  • Fred Schwarzer (66yo)

    Chairman of the Board

    • Tenure: 0yrs
  • Stephen Snowdy (49yo)

    CEO, President & Executive Director

    • Tenure: 6.3yrs
  • Zita Peach (54yo)

    Non-Executive Director

    • Tenure: 0yrs
  • Jean Franchi (53yo)

    Non-Executive Director

    • Tenure: 1.8yrs
  • Rosa Lee

    Executive Director of Manufacturing & Engineering

    • Tenure: 2.8yrs
  • Tom Dooley

    Non-Executive Director

    • Tenure: 2.4yrs

Company Information

Visioneering Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Visioneering Technologies, Inc.
  • Ticker: VTI
  • Exchange: ASX
  • Founded: 2008
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: AU$31.133m
  • Shares outstanding: 399.14m
  • Website: https://www.vtivision.com

Number of Employees


Location

  • Visioneering Technologies, Inc.
  • 10745 Westside Way
  • Suite 200
  • Alpharetta
  • Georgia
  • 30009
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VTIASX (Australian Securities Exchange)Class A Common StockAUAUDNo data
VTIASX (Australian Securities Exchange)YesCDI 1:1AUAUDMar 2017
VTICHIA (Chi-X Australia)YesCDI 1:1AUAUDMar 2017

Biography

Visioneering Technologies, Inc., a medical device company, engages in the design, manufacture, sale, and distribution of contact lenses in the United States. It offers NaturalVue, a contact lense for adult ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 10:39
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.